Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maraviroc + telaprevir
- Development stage
- Unknown
- Lead developer
- Vertex
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Maraviroc + telaprevir is a combination of two small molecule antiviral drugs. Maraviroc is a CCR5 co-receptor antagonist developed by Pfizer and used in combination with other antiretroviral agents to treat CCR5-tropic HIV-1 infection. It works by blocking the interaction between HIV and the human CCR5 receptor on T-cells, thereby preventing viral entry into host cells[1][4]. Telaprevir is an NS3/4A serine protease inhibitor developed by Vertex Pharmaceuticals for use in combination therapy (with peginterferon alfa and ribavirin) for chronic hepatitis C virus (HCV) genotype 1 infection. It inhibits HCV replication by blocking the cleavage of viral polyproteins necessary for producing mature viral proteins[3][6][8]. Both drugs are approved pharmaceuticals but are not indicated as a fixed-dose or standard clinical combination.
- Other names
- maraviroctelaprevir
02
Targets
CCR5 (C-C chemokine receptor type 5)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on maraviroc + telaprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maraviroc + telaprevir.